Synlogic Stock Forecast, Price & News

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Synlogic in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Synlogic stock.
View analyst ratings for Synlogic or view top-rated stocks.

Wall Street analysts have given Synlogic a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Synlogic wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Synlogic is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Synlogic.

Synlogic, Inc. (NASDAQ:SYBX) issued its quarterly earnings data on Thursday, August, 12th. The biotechnology company reported ($0.28) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.29) by $0.01. The biotechnology company had revenue of $0.25 million for the quarter, compared to the consensus estimate of $0.20 million.
View Synlogic's earnings history.

Synlogic's stock was trading at $1.54 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, SYBX stock has increased by 107.8% and is now trading at $3.20.
View which stocks have been most impacted by COVID-19.

Shares of Synlogic reverse split on Monday, August 28th 2017. The 1-7 reverse split was announced on Friday, August 25th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, August 25th 2017. An investor that had 100 shares of Synlogic stock prior to the reverse split would have 14 shares after the split.

6 equities research analysts have issued 1-year price objectives for Synlogic's shares. Their forecasts range from $9.00 to $15.00. On average, they expect Synlogic's stock price to reach $11.60 in the next year. This suggests a possible upside of 262.5% from the stock's current price.
View analysts' price targets for Synlogic or view top-rated stocks among Wall Street analysts.

Some companies that are related to Synlogic include Silence Therapeutics (SLN), Pharming Group (PHAR), Xenon Pharmaceuticals (XENE), Immuneering (IMRX), Seres Therapeutics (MCRB), Imago BioSciences (IMGO), G1 Therapeutics (GTHX), Rigel Pharmaceuticals (RIGL), Rhythm Pharmaceuticals (RYTM), Pliant Therapeutics (PLRX), Adagene (ADAG), Affimed (AFMD), Spero Therapeutics (SPRO), Albireo Pharma (ALBO) and DiaMedica Therapeutics (DMCAF).
View all of SYBX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Synlogic investors own include Reata Pharmaceuticals (RETA), Approach Resources (AREX), Precision Drilling (PDS), First Financial Bankshares (FFIN), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Corbus Pharmaceuticals (CRBP), Inovio Pharmaceuticals (INO), Rigel Pharmaceuticals (RIGL) and Verastem (VSTM).

Synlogic trades on the NASDAQ under the ticker symbol "SYBX."

Synlogic's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include FMR LLC (15.00%), Vanguard Group Inc. (3.30%), Dimensional Fund Advisors LP (1.82%), Ikarian Capital LLC (1.62%), Alyeska Investment Group L.P. (1.53%) and LMR Partners LLP (0.57%).
View institutional ownership trends for Synlogic.

SYBX stock was sold by a variety of institutional investors in the last quarter, including Ikarian Capital LLC, Squarepoint Ops LLC, Renaissance Technologies LLC, Morgan Stanley, Morgan Stanley, Dimensional Fund Advisors LP, Bank of New York Mellon Corp, and Susquehanna International Group LLP.
View insider buying and selling activity for Synlogic or view top insider-selling stocks.

SYBX stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, Vanguard Group Inc., Alyeska Investment Group L.P., LMR Partners LLP, Maven Securities LTD, Geode Capital Management LLC, Millennium Management LLC, and State Street Corp.
View insider buying and selling activity for Synlogic or or view top insider-buying stocks.

Shares of SYBX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SYBX stock can currently be purchased for approximately $3.20.

Synlogic has a market capitalization of $167.59 million and generates $550,000.00 in revenue each year. The biotechnology company earns $-59,170,000.00 in net income (profit) each year or ($1.65) on an earnings per share basis.

Synlogic employs 72 workers across the globe.

The official website for Synlogic is www.synlogictx.com.

Synlogic is headquartered at 301 Binney St. Suite 402, Cambridge MA, 02142.

Synlogic's mailing address is 301 Binney St. Suite 402, Cambridge MA, 02142. The biotechnology company can be reached via phone at (617) 401-9975 or via email at [email protected].